Seoul National University Bundang Hospital
snubh.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
367
Active
51
Phase 3
22
Total enrollment
1,163,133
Pipeline matrix
Showing 40 of 40 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cilostazol | — | — | — | — | 3 | ||
| Metformin | — | — | — | — | — | 2 | |
| Empagliflozin 10 mg | — | — | — | — | — | 2 | |
| Pioglitazone | — | — | — | — | — | 2 | |
| Clopidogrel | — | — | — | — | 2 | ||
| Omega 3-Atorvastatin | — | — | — | — | — | 1 | |
| Atorvastatin-Ezetimibe | — | — | — | — | — | 1 | |
| Pioglitazone 15 MG [Actos] | — | — | — | — | — | 1 | |
| Empagliflozin 10 MG [Jardiance] | — | — | — | — | — | 1 | |
| Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos] | — | — | — | — | — | 1 | |
| Choline fenofibrate | — | — | — | — | — | 1 | |
| Policosanol | — | — | — | — | — | 1 | |
| Enavogliflozin | — | — | — | — | — | 1 | |
| Cilostazol / Ginko Leaf Dried Ext. | — | — | — | — | — | 1 | |
| Oxaliplatin, 5FU, leucovorin | — | — | — | — | — | 1 | |
| Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin, | — | — | — | — | — | 1 | |
| lenalidomide | — | — | — | — | — | 1 | |
| Lenvanib | — | — | — | — | — | 1 | |
| Rifampicin | — | — | — | — | — | 2 | |
| Methotrexate | — | — | — | — | — | 1 | |
| Cyclosporine | — | — | — | — | — | 1 | |
| Propofol | — | — | — | — | 5 | ||
| Remimazolam | — | — | — | — | — | 3 | |
| levothyroxine | — | — | — | — | — | 1 | |
| 10 day sequential therapy | — | — | — | — | — | 1 | |
| 7 day tailored PPI triple therapy | — | — | — | — | — | 1 | |
| 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin] | — | — | — | — | — | 1 | |
| 7 or 14 days tailored EBMT therapy group | — | — | — | — | — | 1 | |
| Tegoprazan-containing sequential H. pylori eradication therapy | — | — | — | — | — | 1 | |
| Esomeprazole-containing sequential H. pylori eradication therapy | — | — | — | — | — | 1 | |
| Levothyroxine tapering | — | — | — | — | — | 1 | |
| Alectinib | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Erlotinib | — | — | — | — | — | 1 | |
| Trastuzumab + Pertuzumab | — | — | — | — | — | 1 | |
| Trastuzumab emtansine | — | — | — | — | — | 1 | |
| Vemurafenib | — | — | — | — | — | 1 | |
| Bevacizumab + Erlotinib | — | — | — | — | — | 1 | |
| Entrectinib | — | — | — | — | — | 1 | |
| Pralsetinib | — | — | — | — | — | 1 |
Next readouts
- 2025-06-09
- 2025-09-30
- 2026-09
- 2026-12-12
- 2026-12-31
- 2026-12-31
- 2026-12-31
- 2026-12-31
- 2026-12-31
- 2026-12-31
Top conditions
- Stroke15
- Gastric Cancer14
- Diabetes11
- Type 2 Diabetes8
- Neuromuscular Blockade8
- Coronary Artery Disease8
- Sarcopenia7
- Helicobacter Pylori Infection7
Frequently asked questions about Seoul National University Bundang Hospital
- How many clinical trials does Seoul National University Bundang Hospital have on ClinicalTrials.gov?
- Seoul National University Bundang Hospital is listed as the lead sponsor on 367 clinical trials in ClinicalTrials.gov, 51 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Seoul National University Bundang Hospital's trials are in Phase 3?
- 22 of Seoul National University Bundang Hospital's trials are in Phase 3, spread across 40 active drug programs.
- What therapeutic areas does Seoul National University Bundang Hospital focus on?
- Seoul National University Bundang Hospital's most-studied conditions on ClinicalTrials.gov are Stroke, Gastric Cancer, Diabetes, Type 2 Diabetes, Neuromuscular Blockade.
- When are Seoul National University Bundang Hospital's next clinical trial readouts?
- Seoul National University Bundang Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects”, expected around 2025-06-09.